Southport Capital Management’s GSK GSK Stock Holding History

Southport Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,563	Closed	-$252K	–	264
2021 Q4	$252K	Buy	4,563 +332	+8%	+$17.3K	0.04%	283
2021 Q3	$202K	Sell	4,231 -3,808	-47%	-$191K	0.08%	221
2021 Q2	$400K	Sell	8,039 -953	-11%	-$45.8K	0.1%	200
2021 Q1	$401K	Buy	8,992 +1,469	+20%	+$66.7K	0.11%	199
2020 Q4	$346K	Sell	7,523 -619	-8%	-$28.4K	0.12%	158
2020 Q3	$383K	Sell	8,142 -196	-2%	-$9.82K	0.15%	150
2020 Q2	$425K	Sell	8,338 -296	-3%	-$15.2K	0.18%	130
2020 Q1	$409K	Sell	8,634 -22,958	-73%	-$1.22M	0.22%	115
2019 Q4	$1.86M	Sell	31,592 -1,756	-5%	-$97.7K	0.72%	36
2019 Q3	$1.78M	Buy	33,348 +37	+0.1%	+$1.9K	0.8%	34
2019 Q2	$1.67M	Sell	33,311 -4,871	-13%	-$244K	0.76%	40
2019 Q1	$2M	Sell	38,182 -4,336	-10%	-$217K	0.89%	30
2018 Q4	$2.03M	Sell	42,518 -1,605	-4%	-$79K	1.02%	22
2018 Q3	$2.22M	Sell	44,123 -1,559	-3%	-$79.2K	0.94%	26
2018 Q2	$2.3M	Sell	45,682 -3,944	-8%	-$199K	1.04%	25
2018 Q1	$2.42M	Buy	49,626 +5,567	+13%	+$259K	1.08%	27
2017 Q4	$1.95M	Buy	44,059 +1,717	+4%	+$79.3K	0.74%	44
2017 Q3	$2.15M	Buy	42,342 +3,182	+8%	+$161K	0.91%	35
2017 Q2	$2.11M	Buy	39,160 +5,435	+16%	+$290K	0.93%	32
2017 Q1	$1.78M	Buy	33,725 +10,787	+47%	+$547K	1%	31
2016 Q4	$1.1M	Buy	22,938 +1,179	+5%	+$58.2K	0.67%	49
2016 Q3	$1.17M	Buy	21,759 +656	+3%	+$36K	0.82%	39
2016 Q2	$1.14M	Sell	21,103 -430	-2%	-$22.7K	0.64%	46
2016 Q1	$1.09M	Sell	21,533 -386	-2%	-$19.2K	0.7%	50
2015 Q4	$1.11M	Sell	21,919 -2,387	-10%	-$122K	0.71%	48
2015 Q3	$1.17M	Buy	24,306 +56	+0.2%	+$2.92K	0.79%	44
2015 Q2	$1.26M	Sell	24,250 -1,748	-7%	-$98.4K	0.76%	45
2015 Q1	$1.5M	Buy	25,998 +113	+0.4%	+$6.48K	0.89%	38
2014 Q4	$1.38M	Buy	25,885 +3,673	+17%	+$205K	0.83%	39
2014 Q3	$1.28M	Buy	22,212 +15,118	+213%	+$927K	0.84%	41
2014 Q2	$474K	Sell	7,094 -240	-3%	-$16.2K	0.32%	81
2014 Q1	$490K	Sell	7,334 -1,748	-19%	-$118K	0.34%	81
2013 Q4	$606K	Buy	9,082 +762	+9%	+$49.4K	0.43%	74
2013 Q3	$522K	Buy	+8,320	New	+$536K	0.41%	76

Other funds holding GSK

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.78B AUM 5.83% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Southport Capital Management's GSK Position: Q1 2022 in Review

Southport Capital Management sold out of GSK (GSK) in Q1 2022, closing a stake of 4,563 shares — an estimated $252K sold.

Southport Capital Management first reported a position in GSK in Q3 2013 and held it in 34 quarters. The position peaked at $2.42M in Q1 2018. 930 funds tracked by Wall St. Rank hold GSK as of Q1 2022.

Southport Capital Management reported no remaining GSK position as of Q1 2022 after selling out during the quarter.
Southport Capital Management sold 4,563 GSK shares in Q1 2022, an estimated $252K.
Southport Capital Management first reported a position in GSK in Q3 2013 and held it in 34 quarters.
Southport Capital Management's GSK position peaked at $2.42M in Q1 2018.
930 funds tracked by Wall St. Rank held GSK as of Q1 2022.

Based on Southport Capital Management's 13F filing for Q1 2022, filed 25 Apr 2022.